ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients

Monika Lindemann; Oliver Witzke; Peter Lütkes; Melanie Fiedler; Ernst Kreuzfelder; Thomas Philipp; Michael Roggendorf; Hans Grosse-Wilde

doi:10.1016/j.clim.2006.03.002

ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients

Monika Lindemann, Oliver Witzke, Peter Lütkes, Melanie Fiedler, Ernst Kreuzfelder, Thomas Philipp, Michael Roggendorf, Hans Grosse-Wilde

University Hospital of Essen

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Enhanced cellular immunity following influenza vaccination has been undetectable in kidney transplant recipients so far. Protection from influenza is dependent on cellular and humoral immunity. Aim of the study was to investigate immune responses before and after vaccination with influenza A and B antigens in 65 kidney transplant recipients. A significant increase in proliferative responses was only observed towards influenza B (P < 0.0001) by lymphocyte transformation test. The enzyme-linked immunospot (ELISpot) assay was more sensitive and detected significant, 3- to 5-fold increases (P < 0.0001) in interferon-γ secretion using influenza A and B antigens. Furthermore, influenza antibody titers increased significantly (P < 0.0001). At month 1 post-vaccination 85% of patients displayed specific cellular, and 95% or 92% humoral immunity against influenza A and B, respectively. Thus, applying the sensitive ELISpot assay, influenza-specific cellular immunity could be detected for the first time in kidney transplant recipients after vaccination.

Original language	English
Pages (from-to)	342-348
Number of pages	7
Journal	Clinical Immunology
Volume	120
Issue number	3
DOIs	https://doi.org/10.1016/j.clim.2006.03.002
State	Published - Sep 2006
Externally published	Yes

Keywords

Cellular immunity
ELISpot
Influenza vaccination
Kidney transplantation
Lymphocyte transformation test

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clim.2006.03.002

Cite this

@article{4994d76cefe84f769c1d1e78812a2814,

title = "ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients",

abstract = "Enhanced cellular immunity following influenza vaccination has been undetectable in kidney transplant recipients so far. Protection from influenza is dependent on cellular and humoral immunity. Aim of the study was to investigate immune responses before and after vaccination with influenza A and B antigens in 65 kidney transplant recipients. A significant increase in proliferative responses was only observed towards influenza B (P < 0.0001) by lymphocyte transformation test. The enzyme-linked immunospot (ELISpot) assay was more sensitive and detected significant, 3- to 5-fold increases (P < 0.0001) in interferon-γ secretion using influenza A and B antigens. Furthermore, influenza antibody titers increased significantly (P < 0.0001). At month 1 post-vaccination 85% of patients displayed specific cellular, and 95% or 92% humoral immunity against influenza A and B, respectively. Thus, applying the sensitive ELISpot assay, influenza-specific cellular immunity could be detected for the first time in kidney transplant recipients after vaccination.",

keywords = "Cellular immunity, ELISpot, Influenza vaccination, Kidney transplantation, Lymphocyte transformation test",

author = "Monika Lindemann and Oliver Witzke and Peter L{\"u}tkes and Melanie Fiedler and Ernst Kreuzfelder and Thomas Philipp and Michael Roggendorf and Hans Grosse-Wilde",

year = "2006",

month = sep,

doi = "10.1016/j.clim.2006.03.002",

language = "English",

volume = "120",

pages = "342--348",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients

AU - Lindemann, Monika

AU - Witzke, Oliver

AU - Lütkes, Peter

AU - Fiedler, Melanie

AU - Kreuzfelder, Ernst

AU - Philipp, Thomas

AU - Roggendorf, Michael

AU - Grosse-Wilde, Hans

PY - 2006/9

Y1 - 2006/9

N2 - Enhanced cellular immunity following influenza vaccination has been undetectable in kidney transplant recipients so far. Protection from influenza is dependent on cellular and humoral immunity. Aim of the study was to investigate immune responses before and after vaccination with influenza A and B antigens in 65 kidney transplant recipients. A significant increase in proliferative responses was only observed towards influenza B (P < 0.0001) by lymphocyte transformation test. The enzyme-linked immunospot (ELISpot) assay was more sensitive and detected significant, 3- to 5-fold increases (P < 0.0001) in interferon-γ secretion using influenza A and B antigens. Furthermore, influenza antibody titers increased significantly (P < 0.0001). At month 1 post-vaccination 85% of patients displayed specific cellular, and 95% or 92% humoral immunity against influenza A and B, respectively. Thus, applying the sensitive ELISpot assay, influenza-specific cellular immunity could be detected for the first time in kidney transplant recipients after vaccination.

AB - Enhanced cellular immunity following influenza vaccination has been undetectable in kidney transplant recipients so far. Protection from influenza is dependent on cellular and humoral immunity. Aim of the study was to investigate immune responses before and after vaccination with influenza A and B antigens in 65 kidney transplant recipients. A significant increase in proliferative responses was only observed towards influenza B (P < 0.0001) by lymphocyte transformation test. The enzyme-linked immunospot (ELISpot) assay was more sensitive and detected significant, 3- to 5-fold increases (P < 0.0001) in interferon-γ secretion using influenza A and B antigens. Furthermore, influenza antibody titers increased significantly (P < 0.0001). At month 1 post-vaccination 85% of patients displayed specific cellular, and 95% or 92% humoral immunity against influenza A and B, respectively. Thus, applying the sensitive ELISpot assay, influenza-specific cellular immunity could be detected for the first time in kidney transplant recipients after vaccination.

KW - Cellular immunity

KW - ELISpot

KW - Influenza vaccination

KW - Kidney transplantation

KW - Lymphocyte transformation test

UR - http://www.scopus.com/inward/record.url?scp=33746810529&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2006.03.002

DO - 10.1016/j.clim.2006.03.002

M3 - Article

C2 - 16631409

AN - SCOPUS:33746810529

SN - 1521-6616

VL - 120

SP - 342

EP - 348

JO - Clinical Immunology

JF - Clinical Immunology

IS - 3

ER -

ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this